Publications by authors named "M Imbimbo"

Claim this Profile
A
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of Mutations.
Lucia Motta, Samantha Epistolio, Jana Pankovics, Francesca Molinari, Benjamin Pedrazzini, Martina Imbimbo

Cancers (Basel)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK).
K-L Koster, I Colombo, S Hayoz, K Eckhardt, A Rojas Mora, M Imbimbo

ESMO Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19).
Alfredo Addeo, Daniel Dietrich, Nicolas Mach, Michael Thomas Mark, Markus Joerger, Martina Imbimbo

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.
John Powderly, Martina Imbimbo, Antoine Italiano, Patricia Martin-Romano, Meredith McKean

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.
Lucia Motta, Francesca Molinari, Jana Pankovics, Benjamin Pedrazzini, Alexandra Valera, Martina Imbimbo

J Clin Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis